日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Semiquantitative CLDN18 expression and clinical outcomes in patients with CLDN18-positive gastric cancer treated with zolbetuximab plus chemotherapy

半定量CLDN18表达与接受佐贝妥昔单抗联合化疗治疗的CLDN18阳性胃癌患者的临床结局

期刊:
影响因子:
doi:10.1016/j.esmogo.2026.100304
Ooki, A; Nakano, K; Shimozaki, K; Takamatsu, M; Fukuoka, S; Sakata, S; Osumi, H; Yoshikawa, K; Toyokawa, E; Yoshino, K; Udagawa, S; Wakatsuki, T; Ogura, M; Shinozaki, E; Chin, K; Kawachi, H; Yamaguchi, K
胃癌
CLDN1
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

BevRam-GC01 study protocol: a phase I trial of bevacizumab plus ramucirumab and paclitaxel in advanced gastric cancer

BevRam-GC01 研究方案：贝伐珠单抗联合雷莫芦单抗和紫杉醇治疗晚期胃癌的 I 期临床试验

期刊:
影响因子:
doi:10.1016/j.esmogo.2025.100299
Wakatsuki, T; Mashima, T; Miyazaki, N; Osumi, H; Fukuoka, S; Ooki, A; Shimozaki, K; Ogura, M; Yoshino, K; Udagawa, S; Shinozaki, E; Chin, K; Ishida, N; Seimiya, H; Yamaguchi, K
胃癌
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

The clinical utility of an mGPS and SII combined score in patients with advanced gastric cancer treated with nivolumab monotherapy

mGPS 和 SII 联合评分在接受纳武利尤单抗单药治疗的晚期胃癌患者中的临床应用价值

期刊:
影响因子:
doi:10.1016/j.esmogo.2025.100177
Udagawa, S; Ooki, A; Osumi, H; Yoshino, K; Tamba, M; Shimozaki, K; Fukuoka, S; Wakatsuki, T; Ogura, M; Shinozaki, E; Chin, K; Yamaguchi, K
胃癌
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Real-world clinical impact of first-line immune checkpoint inhibitor-based therapy in advanced esophageal squamous cell carcinoma

一线免疫检查点抑制剂疗法在晚期食管鳞状细胞癌中的真实临床影响

期刊:
影响因子:
doi:10.1016/j.esmogo.2025.100171
Tamba, M; Chin, K; Osumi, H; Ogura, M; Fukuoka, S; Udagawa, S; Shimozaki, K; Yoshino, K; Wakatsuki, T; Shinozaki, E; Yamaguchi, K; Ooki, A
细胞生物学
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2025
文献求助 收藏

Clinical efficacy of nivolumab-based therapy for HER2-negative diffuse-type advanced gastric or gastroesophageal junction adenocarcinoma with peritoneal dissemination

纳武利尤单抗治疗伴有腹膜播散的HER2阴性弥漫型晚期胃癌或胃食管交界处腺癌的临床疗效

期刊:
影响因子:
doi:10.1016/j.esmogo.2025.100143
Suzuki, Y; Shimozaki, K; Udagawa, S; Chin, K; Osumi, H; Fukuoka, S; Yoshino, K; Tamba, M; Wakatsuki, T; Ogura, M; Shinozaki, E; Yamaguchi, K; Ooki, A
胃癌
肿瘤
肿瘤免疫
HER2
发表日期：2025
文献求助 收藏

Managing zolbetuximab-induced nausea and vomiting: a proposal for a pragmatic approach in clinical practice

佐贝妥昔单抗引起的恶心和呕吐的管理：临床实践中一种务实的治疗方法

期刊:
影响因子:
doi:10.1016/j.esmogo.2024.100128
Shimozaki, K; Ooki, A; Yamahata, Y; Aoyama, T; Yoshino, K; Tamba, M; Udagawa, S; Fukuoka, S; Osumi, H; Wakatsuki, T; Shinozaki, E; Ogura, M; Chin, K; Yamaguchi, K
发表日期：2025
文献求助 收藏

Prognostic nutritional index as a prognostic marker in metastatic esophageal squamous-cell carcinoma treated with immune checkpoint inhibitor

预后营养指数作为免疫检查点抑制剂治疗转移性食管鳞状细胞癌的预后标志物

期刊:
影响因子:
doi:10.1016/j.esmogo.2025.100222
Yoshino, K; Tamba, M; Osumi, H; Fukuoka, S; Ogura, M; Udagawa, S; Shimozaki, K; Wakatsuki, T; Shinozaki, E; Yamaguchi, K; Chin, K; Ooki, A
细胞生物学
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2025
文献求助 收藏

Safety and efficacy of first-line nivolumab plus chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: real-world data analysis

一线纳武利尤单抗联合化疗治疗HER2阴性晚期胃癌或胃食管交界处腺癌的安全性和有效性：真实世界数据分析

期刊:
影响因子:
doi:10.1016/j.esmogo.2024.100072
Shimozaki, K; Fukuda, K; Ooki, A; Nakayama, I; Yoshino, K; Tamba, M; Udagawa, S; Fukuoka, S; Osumi, H; Wakatsuki, T; Takahari, D; Shinozaki, E; Ogura, M; Chin, K; Yamaguchi, K
胃癌
肿瘤
肿瘤免疫
HER2
发表日期：2024
文献求助 收藏

Real-world outcomes of trifluridine/tipiracil for heavily pretreated patients with advanced gastric cancer

三氟尿苷/替吡嘧啶治疗既往接受过大量治疗的晚期胃癌患者的真实世界疗效

期刊:
影响因子:
doi:10.1016/j.esmogo.2024.100046
Fukuda, K; Nakayama, I; Ooki, A; Kamiimabeppu, D; Shimozaki, K; Osumi, H; Fukuoka, S; Yoshino, K; Ogura, M; Wakatsuki, T; Chin, K; Shinozaki, E; Yamaguchi, K; Takahari, D
胃癌
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma

低HER2表达、不可手术、晚期或复发性胃/胃食管交界处腺癌的发病率、临床病理特征和临床结局

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2023.101582
Nakayama, I; Takahari, D; Chin, K; Wakatsuki, T; Takamatsu, M; Yamamoto, N; Ogura, M; Ooki, A; Fukuda, K; Osumi, H; Fukuoka, S; Shinozaki, E; Yamaguchi, K
肿瘤
肿瘤免疫
HER2
发表日期：2023
文献求助 收藏